Elaitra

London, United Kingdom All United Kingdom companies → — Founded 2015

Imaging AI Specialist Specialty-Focused AI

Oncology Radiology

Oncology AI Radiology & Imaging AI

Generating Revenue — $1.28M

Claim this company

Products

ViewFinder Software Version

Elaitra

Oncology AI

Elaitra's ViewFinder is an FDA-cleared AI tool that enhances Digital Breast Tomosynthesis (DBT) interpretation by providing real-time, dynamic cross-view tissue matching, improving radiologist efficiency and diagnostic accuracy in breast cancer screening.

Not disclosed

See all 1 product →

About Elaitra

Elaitra is a UK-based healthcare AI company specializing in advanced medical imaging solutions for breast cancer detection. The company’s core offering, ViewFinder, is an FDA-cleared AI tool designed to enhance the efficiency and accuracy of breast cancer screening using digital breast tomosynthesis (DBT). ViewFinder functions as an interactive or ’embodied’ AI system, providing real-time visual guidance to radiologists during image interpretation. This technology helps in accurately correlating tissue areas across different views in 3D mammography, thereby reducing localization errors and increasing diagnostic confidence, particularly for identifying very small lesions.

By augmenting the radiologist’s spatial reasoning rather than replacing it, Elaitra’s ViewFinder aims to streamline clinical workflows and improve patient outcomes by enabling earlier and more precise cancer detection. A peer-reviewed study published in the European Journal of Radiology demonstrated that ViewFinder significantly reduces localization errors across various case types and boosts confidence among radiologists of all skill levels. The company’s approach focuses on human-AI interaction to address critical pain points in breast imaging.

Focus Areas

AI-powered medical imaging breast cancer detection digital breast tomosynthesis (DBT) enhancing spatial reasoning for radiologists human-AI interaction in medical imaging

Business Intelligence

Key Investors	Alchemist Accelerator, SFC Capital, Cancer Tech Accelerator, Innovate UK, Cancer Research Horizons
Partnerships	DeepLook Medical
Technology	Cloud-native (implied by integration capabilities), AI operating system (proprietary 'embodied AI' for ViewFinder), standalone software application or integrated into medical image management and processing systems
FDA Clearances	1 cleared products (estimated)

What Physicians Need to Know

AI-Powered Medical Imaging

Elaitra specializes in AI-powered medical imaging, particularly for breast cancer detection using Digital Breast Tomosynthesis (DBT). Their flagship product, ViewFinder, is an FDA-cleared AI tool designed to make breast cancer screening easier and quicker for radiographers.

Breast Cancer Detection & DBT

The company's core focus is on improving breast cancer detection through advanced 3D mammography (DBT). ViewFinder significantly reduces localization errors across normal, benign, and abnormal cases, enhancing accuracy and sensitivity over conventional 2D scanning.

Enhancing Spatial Reasoning for Radiologists

Elaitra's ViewFinder augments radiologists' spatial reasoning rather than replacing it. It provides real-time visual guidance to help accurately match the same tissue area across different DBT views, improving 3D navigation and reducing guesswork, especially for small lesions.

Human-AI Interaction in Medical Imaging

Elaitra employs a proprietary 'human-in-the-loop' or 'embodied AI' approach, focusing on seamless human-AI interaction. This collaborative system aims for collective performance that exceeds what either a human or AI could achieve alone, improving diagnostic accuracy and communication during work-ups.

Key Differentiators

ViewFinder is an FDA-cleared, fourth-generation proprietary AI tool backed by peer-reviewed studies published in the European Journal of Radiology. It offers dynamic tissue matching, significantly improving localization accuracy, particularly for less experienced readers and challenging cases. The technology also qualifies for immediate 'by report' reimbursement in the USA.

Technology Stack (Core & Deployment)

Elaitra leverages deep learning algorithms and a proprietary AI approach for its ViewFinder product. The AI-enabled tool is vendor-agnostic and supports flexible deployment options, including on-premises or through approved cloud providers. They also partner with companies like Ferrum Health for AI governance and deployment solutions.

Physician Tip

For physicians, Elaitra's ViewFinder offers a significant advantage by enhancing diagnostic accuracy and confidence in DBT interpretation, especially in complex cases and for less experienced radiologists. The system's real-time visual guidance and 'human-in-the-loop' AI design mean it acts as a cognitive partner, streamlining workflow and potentially reducing interpretation time without replacing clinical judgment. Its FDA clearance and demonstrated reimbursement potential also provide practical benefits for adoption.

Elaitra's ViewFinder is designed to be vendor-agnostic, allowing for deployment on-premises or via approved cloud providers, which facilitates integration into existing radiology workflows. Their collaboration with partners like Ferrum Health further supports seamless AI governance and deployment across various healthcare IT infrastructures.

At a glance

Founded 2015

HQ London, United Kingdom · United Kingdom

Team size 5

CEO Stephen Morrell

Funding Generating Revenue — $1.28M

FDA clearances 1 (estimated)

Products 1

Products by Elaitra

1 product in the directory

ViewFinder Software Version

Elaitra

Oncology AI

Not disclosed

Reviews & Opinions

No web reviews on file yet for Elaitra. Check back later for aggregated opinions from across the web.

Videos

News, demos, and interviews about Elaitra.

Loading videos...

Videos load interactively. If none appear, search YouTube for Elaitra →

View all on YouTube

Press & Coverage

King's College London

ViewFinder AI brings cross view precision to 3D mammography

Elaitra, a medical imaging startup, launched ViewFinder, an FDA-cleared AI tool designed to make breast cancer screening using digital breast tomosynthesis (DBT) easier and quicker for radiographers by providing real-time visual guidance.

2025-11

DVT Insights

The Gen AI Playbook that delivers real ROI | DVT Insights featuring Stephen Morrel

Stephen Morrell, CEO of Elaitra AI, discussed how generative AI is delivering real business value, with Elaitra AI generating u00a319M in revenue and processing 180K AI conversations, and developing AI models that outperformed Google DeepMind in detecting cancer.

2025-03

FDA

510(k) Premarket Notification - Elaitra, Ltd.

The FDA issued a 510(k) premarket notification for Elaitra, Ltd.'s device, determining it substantially equivalent to legally marketed predicate devices for breast cancer screening.

2023-04

VCBacked

Elaitra Funding & Investors - Pre-Seed - San Francisco | VCBacked

Elaitra has raised $761K in total funding, with its most recent round being Pre-Seed, announced in June 2023.

2023-06

Cancer Tech Accelerator

Company Profiles: Stephen Morrell, Elaitra | Cancer Tech Accelerator

Stephen Morrell, CEO of Elaitra, developed ViewFinder, a GPS for 3D medical images that improves breast cancer detection. Elaitra received regulatory approval from MHRA and u00a370,000 in grant funding from the Cancer Tech Accelerator program.

2022-01

PMC (PubMed Central)

Revolutionizing Breast Cancer Detection With Artificial Intelligence (AI) in Radiology and Radiation Oncology: A Systematic Review - PMC

This systematic review discusses the latest developments and applications of AI in breast cancer screening and treatment, highlighting its potential for more accurate and efficient automated detection.

2024-04

AI Centre for Value Based Healthcare

Breast Cancer | AI Centre for Value Based healthcare

Elaitra is partnering with Thames Mammography to create a prototype AI-enabled clinical workflow that can interpret both FFDM and DBT images and automatically detect abnormal results for breast cancer.

unknown

Frequently Asked Questions

How does Elaitra's AI platform enhance breast cancer detection, particularly when utilizing Digital Breast Tomosynthesis (DBT)?

Elaitra's AI leverages advanced algorithms to analyze DBT images, identifying subtle anomalies that may be missed by the human eye. This technology assists radiologists in detecting breast cancers earlier and with greater accuracy, improving diagnostic confidence and patient outcomes.

How does Elaitra's technology specifically aid radiologists in improving their spatial reasoning and interpretation of complex medical images?

Our AI provides intelligent visualizations and quantitative metrics that highlight areas of concern and anatomical relationships within 3D DBT datasets. This augmentation helps radiologists better understand complex spatial arrangements, reducing interpretation time and enhancing diagnostic precision.

What is Elaitra's approach to ensuring effective human-AI interaction, addressing concerns like alert fatigue, bias, or over-reliance on AI in medical imaging?

Elaitra designs its AI as an assistive tool, not a replacement for human expertise. We focus on explainable AI, configurable sensitivity settings, and intuitive interfaces to minimize alert fatigue and maintain the radiologist as the final decision-maker, fostering optimal collaboration.

What specific AI-powered products or solutions does Elaitra offer for breast imaging departments?

Elaitra offers a suite of AI solutions including an AI-powered CAD (Computer-Aided Detection) system for DBT, a risk stratification tool, and a workflow optimization module. These products are designed to integrate seamlessly into existing PACS and RIS systems to streamline operations.

How does Elaitra ensure regulatory compliance (e.g., FDA, HIPAA, GDPR) for its AI-powered medical imaging solutions?

Elaitra adheres to the highest standards of regulatory compliance, including FDA clearance/CE Mark, HIPAA for patient data privacy, and GDPR for data protection. Our development processes incorporate rigorous validation, clinical trials, and cybersecurity protocols to meet global health regulations.

What is Elaitra's typical pricing model for its AI solutions, and what factors influence the cost for healthcare providers?

Elaitra offers flexible pricing models, which may include subscription-based licensing per study, per workstation, or enterprise-wide agreements. Costs are typically influenced by the scale of deployment, specific modules chosen, and the level of integration required.

What kind of technical support, training, and ongoing service does Elaitra provide to its customers?

Elaitra provides comprehensive support including initial implementation and integration services, extensive training for radiologists and technologists, and 24/7 technical support. We also offer regular software updates and performance monitoring to ensure optimal system operation.

What strategic partnerships has Elaitra formed, and what is the company's long-term vision and stability in the evolving AI healthcare market?

Elaitra actively collaborates with leading academic institutions, medical device manufacturers, and research organizations to advance our technology. We are a well-funded company with a clear long-term vision focused on continuous innovation and expanding our AI solutions across various imaging modalities.

Related Companies

Suggest an Edit →